Date: 2013-10-14
Type of information: Services contract
Compound:
Company: Argenta (Galapagos subsidiary – UK Belgium) Genentech, a member of the Roche Group (Switzerland - USA)
Therapeutic area: undisclosed
Type agreement: R&D
services
Action mechanism:
Disease:
Details: * On October 14, 2013, Argenta, a Galapagos company that provides drug discovery services from target validation to proof of concept, has announced a three-year extension of its integrated contract drug discovery agreement with Genentech, a member of the Roche Group. This is the fourth such extension since the agreement was first announced in December 2005. The agreement covers a portfolio of projects that utilizes Argenta\'s wide-ranging drug discovery expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
Financial terms:
Latest news:
